Median Technologies has successfully raised €50.0 million in a capital increase, marking a significant follow-on funding round. This capital injection will primarily fuel the expansion of its eyonis® AI platform and bolster its commercial operations. The company aims to leverage this funding to accelerate its growth in the oncology clinical trials market.